GLP1R and chronic kidney disease: Clinical trials, including LEADER, SUSTAIN-6, and REWIND, have shown that specific GLP-1 RAs can lower the risk of MACE and slow the progression of CKD by improving outcomes related to albuminuria; data that are scarcely evaluated by real-world Romanian studies [24].